6 completed, 1 terminated, 1 unknown. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow Herantis Pharma Plc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease HER-096, Placebo - Parkinson Disease, Idiopathic | Phase 1 | Completed | Herantis Pharma Plc. | 32 | 2024-09-23 | 2025-09-12 |
| Single Ascending Doses of HER-096 in Healthy Subjects HER-096, Placebo - Parkinson Disease | Phase 1 | Completed | Herantis Pharma Plc. | 60 | 2023-03-29 | 2023-10-27 |
| Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions Renishaw Drug Delivery System - Parkinson Disease, Movement Disorders | Phase 1 / Phase 2 | Unknown | Renishaw | 15 | 2019-03-20 | 2021-03-23 |
| Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System - Parkinson Disease, Movement Disorders | Phase 1 / Phase 2 | Completed | Herantis Pharma Plc. | 15 | 2018-07-05 | 2020-08-12 |
| Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE) Lymfactin® (1x10E11 vp), Placebo - Secondary Lymphedema | Phase 2 | Completed | Herantis Pharma Plc. | 39 | 2018-06-07 | 2025-07-09 |
| Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System - Parkinson Disease, Movement Disorders | Phase 1 / Phase 2 | Completed | Herantis Pharma Plc. | 17 | 2017-09-26 | 2020-01-13 |
| A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema Lymfactin® [1 x 10E10 vp], Lymfactin® [1 x 10E11 vp] - Secondary Lymphedema | Phase 1 | Terminated | Herantis Pharma Plc. | 15 | 2016-06-01 | 2023-04-24 |
| Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye cis-UCA ophthalmic solution 1.0%, cis-UCA ophthalmic solution 2.5%, Placebo ophthalmic solution - Dry Eye Syndrome | Phase 2 | Completed | Herantis Pharma Plc. | 161 | 2014-12-01 | 2015-09-09 |
Parkinson Disease (5) · Brain Diseases (3) · Movement Disorders (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Central Nervous System Diseases (2) · Basal Ganglia Diseases (1) · Breast Cancer Lymphedema (1) · Breast Neoplasms (1) · Dry Eye Syndromes (1) · Lymphedema (1) · Parkinsonian Disorders (1)
Sodium Chloride (2)
Finland (7) · Sweden (4) · United States (1)
Anne Saarikko, MD, PhD (2) · Aleksi Tornio, MD (1) · Maria Mani, MD, PhD (1) · Per Svenningsson, MD (1) · Per Svenningsson, MD, Prof. (1) · Prof. Juha Rinne, MD, PhD (1)
2015 (1), 2017 (1)